Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from China Pharma Holdings ( (CPHI) ) is now available.
On December 22, 2025, Hainan Helpson Medical & Biotechnology Co., Ltd., a wholly owned subsidiary of China Pharma Holdings, entered into a Technology Transfer Agreement with patent holder Juan Zhang to acquire full ownership of an invention patent covering Ipragliflozin tablets and their preparation method. As part of the deal, the transferor or a designated third party will provide a suite of technical services, including product research and development and preparation and submission of registration materials, underscoring China Pharma’s efforts to expand its drug portfolio. The $9.8 million purchase price will be paid in China Pharma common stock valued at $1.40 per share, resulting in the planned issuance of 7,000,000 restricted shares to a non-U.S. person in an offshore transaction exempt from U.S. securities registration requirements, a move that both conserves cash and potentially dilutes existing shareholders while supporting the company’s pipeline development.
The most recent analyst rating on (CPHI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on China Pharma Holdings stock, see the CPHI Stock Forecast page.
Spark’s Take on CPHI Stock
According to Spark, TipRanks’ AI Analyst, CPHI is a Neutral.
China Pharma Holdings faces significant financial challenges, with negative profitability and cash flow metrics being the most impactful factors. The technical analysis suggests a bearish trend, but the stock is nearing oversold conditions. Valuation metrics are unattractive due to negative earnings. The recent patent acquisition is a positive strategic move, but it does not outweigh the financial distress. Overall, the stock score reflects these challenges and opportunities.
To see Spark’s full report on CPHI stock, click here.
More about China Pharma Holdings
China Pharma Holdings, through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd, operates in the pharmaceutical and biotechnology industry, with a focus on developing and manufacturing drug products such as specialty tablets for therapeutic use.
Average Trading Volume: 24,298
Technical Sentiment Signal: Sell
Current Market Cap: $7.08M
Learn more about CPHI stock on TipRanks’ Stock Analysis page.